TRIZYTEK Trademark

Trademark Overview

On Wednesday, August 4, 2021, a trademark application was filed for TRIZYTEK with the United States Patent and Trademark Office. The USPTO has given the TRIZYTEK trademark a serial number of 90864602. The federal status of this trademark filing is REQUEST FOR THIRD EXTENSION - FILED as of Friday, April 19, 2024. This trademark is owned by Acorda Therapeutics, Inc.. The TRIZYTEK trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical and biological compositions used in the treatment of neurological diseases, disorders or conditions
trizytek

General Information

Serial Number90864602
Word MarkTRIZYTEK
Filing DateWednesday, August 4, 2021
Status720 - REQUEST FOR THIRD EXTENSION - FILED
Status DateFriday, April 19, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 30, 2022

Trademark Statements

Goods and Servicespharmaceutical and biological compositions used in the treatment of neurological diseases, disorders or conditions

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 29, 2021
Primary Code005
First Use Anywhere DateThursday, January 1, 1970
First Use In Commerce DateThursday, January 1, 1970

Trademark Owner History

Party NameAcorda Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPearl River, US 10965
Party NameAcorda Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressArdsley, US 10502

Trademark Events

Event DateEvent Description
Thursday, December 2, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Saturday, August 7, 2021NEW APPLICATION ENTERED
Wednesday, September 29, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 2, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, December 2, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, December 2, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, December 2, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, January 28, 2022ASSIGNED TO EXAMINER
Friday, January 28, 2022NON-FINAL ACTION WRITTEN
Friday, January 28, 2022NON-FINAL ACTION E-MAILED
Friday, January 28, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, July 22, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, July 22, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 22, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, July 22, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 10, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 30, 2022PUBLISHED FOR OPPOSITION
Tuesday, August 30, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 25, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 18, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, April 18, 2023SOU EXTENSION 1 FILED
Tuesday, April 18, 2023SOU EXTENSION 1 GRANTED
Thursday, April 20, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 16, 2023ASSIGNED TO EXAMINER
Wednesday, October 18, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, October 18, 2023SOU EXTENSION 2 FILED
Wednesday, October 18, 2023SOU EXTENSION 2 GRANTED
Friday, October 20, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 19, 2024SOU TEAS EXTENSION RECEIVED
Friday, April 19, 2024SOU EXTENSION 3 FILED
Friday, April 19, 2024SOU EXTENSION 3 GRANTED
Saturday, April 20, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

trizytek diseases disorders conditions neurological treatment biological compositions used pharmaceutical